J Drugs Dermatol. 2023 Oct 1;22(10):1053-1057. doi: 10.36849/JDD.7540.
Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10): doi:10.36849/JDD.7540.
角化病是一组罕见的获得性或遗传性皮肤病，其特征为具有角化边界的线性或环形斑块。DSAP 是最常见的角化病，病变范围从无症状到瘙痒的圆形粉红色到棕色斑疹、丘疹或斑块，周围有凸起的边界。DSAP 发生 SCC 或 BCC 恶变的风险约为 7.5-10%。尽管过去 DSAP 广泛采用外用双氯芬酸、 ingenol mebutate、外用维生素 D 类似物、5-氟尿嘧啶、咪喹莫特、光动力疗法、类视黄醇、冷冻疗法和激光疗法进行治疗，但这些疗法的疗效有限，并导致不良反应，包括炎症反应、色素沉着、疼痛和红斑。最近，一种局部他汀类药物和胆固醇的配方作为治疗 DSAP 的新方法出现，与目前的治疗方法相比，它显示出临床改善，且不良反应可耐受。在总共 8 项针对 20 名 DSAP 患者的病例研究中，90%（18/20）的患者报告说各种形式的局部他汀类药物治疗均有临床改善。虽然有希望，但需要更大的随机对照试验来评估长期使用局部他汀类药物治疗 DSAP 的情况。J Drugs Dermatol. 2023;22(10): doi:10.36849/JDD.7540.
